ATR and neoplasm: Supplementary Table S2 summarizes ongoing clinical trials evaluating the combination of ATR inhibitors and immune checkpoint inhibitors across multiple tumor types, many of which are still actively enrolling participants, highlighting sustained interest in this therapeutic strategy.